Table 1. DR5 expression levels in GBM tumors correlates with nuclear BNIP3 levels.
DR5 expression |
||||
---|---|---|---|---|
BNIP3 localization | Expressed (0–1+) | Overexpressed (2+) | Strongly overexpressed (3+) | Total |
Actual | ||||
Nuclear (3+) | 3 | 3 | 1 | 7 |
Moderate nuclear (2+) | 9 | 0 | 0 | 9 |
Low nuclear (0–1+) | 6 | 2 | 6 | 14 |
Expected | ||||
Nuclear (3+) | 2.33 | 2.33 | 2.33 | 7 |
Moderate nuclear (2+) | 3 | 3 | 3 | 9 |
Low nuclear (0–1+) | 4.67 | 4.67 | 4.67 | 14 |
Chi-squared | 0.00026 |
A total of 14 GBM tumors were scored for BNIP3 localization and then graded for DR5 expression levels. We predict that there would be an even distribution of DR5 expression across the different levels of BNIP3; however, tumors that had high levels of BNIP3 in the nucleus had lower levels of DR5, and when there were lower levels of BNIP3 in the nucleus there were higher levels of DR5. Chi square analysis showed that these differences were highly significant (P<0.001).